Skip to main content
. 2017 Mar 6;28(6):1939–1950. doi: 10.1007/s00198-017-3973-8

Table 2.

Results of scenario analysis on treatment persistence

10-year fracture probability (%) RR of hip fracture RR of major fracture QALYs Incremental
QALYs
Cost (USD) Incremental
cost (USD)
ICER (USD per QALY) INMB
(USD)
Hip fracture Vertebral fracture Other fracture
70 years old, T-score −2.0
 BT 2.20 9.20 6.20 11.331 17,530
 ALN + BT (vs BT) 2.00 8.30 5.90 0.909 0.920 11.346 0.015 17,830 300 19,904 453
 ZOL + BT (vs ALN + BT) 1.90 7.30 5.50 0.950 0.907 11.356 0.010 18,326 497 47,435 27
65 years old, T-score −2.5
 BT 2.50 9.50 7.00 13.472 23,988
 ALN + BT (vs BT) 2.30 8.60 6.60 0.920 0.921 13.503 0.031 24,029 41 1322 1499
 ZOL + BT (vs ALN + BT) 2.20 7.60 6.20 0.957 0.914 13.520 0.017 24,447 418 25,067 416
70 years old, T-score −2.5
 BT 3.60 12.00 7.30 11.167 20,364
 ALN + BT (vs BT) 3.30 10.80 6.90 0.917 0.917 11.193 0.026 20,460 95 3620 1222
 ZOL + BT (vs ALN + BT) 3.10 9.50 6.40 0.939 0.905 11.209 0.015 20,868 408 27,018 347
75 years old, T-score −2.5
 BT 5.20 14.80 7.30 8.905 16,755
 ALN + BT (vs BT) 4.60 13.30 6.80 0.885 0.905 8.934 0.029 16,885 130 4523 1309
 ZOL + BT (vs ALN + BT) 4.40 11.60 6.30 0.957 0.903 8.948 0.014 17,252 367 25,747 346
70 years old, T-score −3.0
 ALN + BT 5.30 14.10 8.10 10.979 24,209
 ZOL + BT (vs ALN + BT) 5.00 12.40 7.50 0.943 0.905 11.000 0.022 24,443 235 10,749 857
 BT (vs ZOL + BT) 66.00 15.70 8.60 1.200 1.217 10.935 −0.065 24,534 91 Dominated −3341

BT: basic treatment (placebo + calcium + vitamin D), ZOL: once-yearly injection of zoledronic acid 5 mg, ALN: once-weekly oral alendronate 35 mg. 1 USD = 120 JPY (February 2016 exchange rate). All strategies were ranked according to costs

RR relative risk, QALYs quality-adjusted life years, ICER incremental cost-effectiveness ratio, INMB incremental net monetary benefit